Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
CNY 5.1
(0.99%)
CNY 5.1
(0.99%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 42.59 Million CNY | -100.15% |
| 2022 | 2.19 Billion CNY | 104.25% |
| 2021 | 1.07 Billion CNY | 129.03% |
| 2020 | 468.83 Million CNY | 200.05% |
| 2019 | 156.25 Million CNY | 24.0% |
| 2018 | 126.01 Million CNY | 14.49% |
| 2017 | 110.06 Million CNY | 36.85% |
| 2016 | 80.42 Million CNY | 11.77% |
| 2015 | 71.96 Million CNY | -0.2% |
| 2014 | 72.1 Million CNY | 117.56% |
| 2013 | 33.14 Million CNY | 55.43% |
| 2012 | 21.32 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -99.81 Million CNY | -203.79% |
| 2024 Q1 | -32.85 Million CNY | 69.17% |
| 2024 Q3 | -346.06 Million CNY | -246.7% |
| 2023 Q4 | -106.59 Million CNY | -3964.09% |
| 2023 Q3 | 2.75 Million CNY | -95.72% |
| 2023 FY | -3.22 Million CNY | -100.15% |
| 2023 Q2 | 64.38 Million CNY | 6.17% |
| 2023 Q1 | 60.64 Million CNY | -73.09% |
| 2022 Q4 | 225.35 Million CNY | -65.75% |
| 2022 Q2 | 637.47 Million CNY | -5.18% |
| 2022 Q1 | 672.32 Million CNY | 153.6% |
| 2022 FY | 2.19 Billion CNY | 104.25% |
| 2022 Q3 | 658.02 Million CNY | 3.22% |
| 2021 Q4 | 265.11 Million CNY | -16.5% |
| 2021 Q2 | 264.31 Million CNY | 16.52% |
| 2021 Q3 | 317.51 Million CNY | 20.13% |
| 2021 FY | 1.07 Billion CNY | 129.03% |
| 2021 Q1 | 226.84 Million CNY | 97.81% |
| 2020 FY | 468.83 Million CNY | 200.05% |
| 2020 Q3 | 179.04 Million CNY | 23.32% |
| 2020 Q1 | 29.92 Million CNY | -33.01% |
| 2020 Q4 | 114.67 Million CNY | -35.95% |
| 2020 Q2 | 145.18 Million CNY | 385.13% |
| 2019 Q2 | 47.44 Million CNY | 175.39% |
| 2019 Q4 | 44.67 Million CNY | -4.77% |
| 2019 Q1 | 17.22 Million CNY | -57.09% |
| 2019 FY | 156.25 Million CNY | 24.0% |
| 2019 Q3 | 46.91 Million CNY | -1.12% |
| 2018 Q1 | 13.72 Million CNY | -55.52% |
| 2018 FY | 126.01 Million CNY | 14.49% |
| 2018 Q4 | 40.14 Million CNY | 18.09% |
| 2018 Q3 | 33.99 Million CNY | -10.87% |
| 2018 Q2 | 38.14 Million CNY | 177.86% |
| 2017 FY | 110.06 Million CNY | 36.85% |
| 2017 Q3 | 33.22 Million CNY | -3.46% |
| 2017 Q4 | 30.86 Million CNY | -7.09% |
| 2017 Q1 | 11.56 Million CNY | -53.72% |
| 2017 Q2 | 34.41 Million CNY | 197.52% |
| 2016 Q3 | 21.85 Million CNY | -14.68% |
| 2016 FY | 80.42 Million CNY | 11.77% |
| 2016 Q2 | 25.62 Million CNY | 222.12% |
| 2016 Q1 | 7.95 Million CNY | 0.0% |
| 2016 Q4 | 24.99 Million CNY | 14.34% |
| 2015 FY | 71.96 Million CNY | -0.2% |
| 2014 FY | 72.1 Million CNY | 117.56% |
| 2013 FY | 33.14 Million CNY | 55.43% |
| 2012 FY | 21.32 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 998.13 Million CNY | 95.732% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion CNY | 98.287% |
| Dirui Industrial Co.,Ltd. | 296.87 Million CNY | 85.651% |
| Beijing Strong Biotechnologies, Inc. | 593.87 Million CNY | 92.827% |
| Medicalsystem Biotechnology Co., Ltd. | 279.11 Million CNY | 84.738% |
| Maccura Biotechnology Co.Ltd | 331.14 Million CNY | 87.136% |
| Guangzhou Wondfo Biotech Co.,Ltd | 549.13 Million CNY | 92.242% |
| BGI Genomics Co., Ltd. | 150.64 Million CNY | 71.723% |
| Amoy Diagnostics Co., Ltd. | 301.24 Million CNY | 85.859% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -135.82 Million CNY | 131.364% |